MX2023006291A - Metodos para purificar proteinas que contienen fc. - Google Patents
Metodos para purificar proteinas que contienen fc.Info
- Publication number
- MX2023006291A MX2023006291A MX2023006291A MX2023006291A MX2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A MX 2023006291 A MX2023006291 A MX 2023006291A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- methods
- purifying
- resin
- elution buffer
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000012149 elution buffer Substances 0.000 abstract 2
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003196 chaotropic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012562 protein A resin Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Storage Device Security (AREA)
Abstract
La presente invención se refiere a métodos para purificar proteínas que contienen regiones Fc, tales como anticuerpos y proteínas de fusión de Fc. En particular, la presente invención se refiere a un método de purificación que da como resultado niveles reducidos de agregados de proteínas que comprende adsorber una proteína que contiene una región Fc en una resina de proteína A sensible a la temperatura y eluir la proteína desde la resina a una temperatura inferior a 35 °C con un tampón de elución que comprende un agente caotrópico, un alcohol de azúcar, y al menos un aminoácido. También se describen métodos para separar los anticuerpos ensamblados por completo de las formas de semianticuerpo de los mismos usando el tampón de elución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365943P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006291A true MX2023006291A (es) | 2023-06-13 |
Family
ID=59656168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000903A MX2019000903A (es) | 2016-07-22 | 2017-07-21 | Metodos para purificar proteinas que contienen fc. |
| MX2023006291A MX2023006291A (es) | 2016-07-22 | 2019-01-21 | Metodos para purificar proteinas que contienen fc. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000903A MX2019000903A (es) | 2016-07-22 | 2017-07-21 | Metodos para purificar proteinas que contienen fc. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11312745B2 (es) |
| EP (1) | EP3487867A2 (es) |
| JP (2) | JP7092744B2 (es) |
| KR (2) | KR102435801B1 (es) |
| CN (2) | CN109563125B (es) |
| AU (2) | AU2017298984B2 (es) |
| CA (2) | CA3031469A1 (es) |
| IL (2) | IL285146B (es) |
| MA (1) | MA45721A (es) |
| MX (2) | MX2019000903A (es) |
| SG (1) | SG11201900573UA (es) |
| WO (1) | WO2018018011A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022501357A (ja) * | 2018-09-21 | 2022-01-06 | テネオバイオ， インコーポレイテッド | ヘテロ二量体多重特異性抗体を精製するための方法 |
| JP2022512636A (ja) * | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | 二重特異性抗体コンストラクトの下流プロセシング |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN110724204B (zh) * | 2019-11-18 | 2021-10-22 | 广东菲鹏制药股份有限公司 | Fc融合蛋白的纯化方法 |
| CN112881675A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏生物有限公司 | IgM抗体检测稀释液 |
| CN116056775A (zh) * | 2020-09-16 | 2023-05-02 | 沃特世科技公司 | 在尺寸排阻色谱流动相中使用低浓度氨基酸的改善尺寸排阻色谱法 |
| CA3235508A1 (en) * | 2021-10-19 | 2023-05-11 | Soon Jae Park | Method for purifying fusion protein having igg fc domain |
| CN113980092B (zh) * | 2021-12-09 | 2024-05-14 | 上海药明生物技术有限公司 | 一种蛋白质亲和纯化方法 |
| CN116271982B (zh) * | 2022-11-30 | 2024-01-09 | 杭州广科安德生物科技有限公司 | 一种血液高丰度蛋白免疫亲和柱的再生方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| JP2002511264A (ja) * | 1998-04-16 | 2002-04-16 | ジェネンテック・インコーポレーテッド | 組織プラスミノーゲン活性化因子プロ配列を使用するグリコシル化タンパク質の分泌 |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR101370253B1 (ko) | 2004-10-22 | 2014-03-05 | 암젠 인크 | 재조합 항체의 재접힘 방법 |
| CA2636109A1 (en) * | 2006-01-06 | 2007-07-19 | Amgen Inc. | Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents |
| MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| US10982250B2 (en) * | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
| WO2008143199A1 (ja) * | 2007-05-21 | 2008-11-27 | Nomadic Bioscience Co., Ltd. | 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法 |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CA2733782A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| MX2011013898A (es) | 2009-06-22 | 2012-05-22 | Amgen Inc | Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado. |
| WO2010151688A2 (en) * | 2009-06-25 | 2010-12-29 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| CN104945509A (zh) * | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| CN102382190B (zh) * | 2010-09-01 | 2014-04-09 | 山东新时代药业有限公司 | 分离和去除TNFR-Fc融合蛋白中寡聚体的方法 |
| JPWO2012086837A1 (ja) | 2010-12-24 | 2014-06-05 | 旭化成メディカル株式会社 | 温度応答性プロテインａの固定化方法 |
| CA2840951A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Methods for purifying fc-fusion protein |
| WO2013147691A1 (en) | 2012-03-28 | 2013-10-03 | Ge Healthcare Bio-Sciences Ab | Affinity chromatography matrix |
| JP6253584B2 (ja) | 2012-08-27 | 2017-12-27 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| SG10201909806SA (en) * | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2017
- 2017-07-21 AU AU2017298984A patent/AU2017298984B2/en active Active
- 2017-07-21 KR KR1020197003162A patent/KR102435801B1/ko active IP Right Grant
- 2017-07-21 JP JP2019503247A patent/JP7092744B2/ja active Active
- 2017-07-21 CN CN201780045463.1A patent/CN109563125B/zh active Active
- 2017-07-21 US US16/093,994 patent/US11312745B2/en active Active
- 2017-07-21 MX MX2019000903A patent/MX2019000903A/es unknown
- 2017-07-21 CA CA3031469A patent/CA3031469A1/en active Pending
- 2017-07-21 SG SG11201900573UA patent/SG11201900573UA/en unknown
- 2017-07-21 CA CA3218290A patent/CA3218290A1/en active Pending
- 2017-07-21 IL IL285146A patent/IL285146B/en unknown
- 2017-07-21 WO PCT/US2017/043384 patent/WO2018018011A2/en unknown
- 2017-07-21 EP EP17754514.2A patent/EP3487867A2/en active Pending
- 2017-07-21 MA MA045721A patent/MA45721A/fr unknown
- 2017-07-21 CN CN202210979746.6A patent/CN115925780A/zh active Pending
- 2017-07-21 KR KR1020227028721A patent/KR102579850B1/ko active IP Right Grant
-
2019
- 2019-01-21 IL IL264375A patent/IL264375B/en unknown
- 2019-01-21 MX MX2023006291A patent/MX2023006291A/es unknown
-
2022
- 2022-06-15 JP JP2022096278A patent/JP7411020B2/ja active Active
-
2023
- 2023-08-31 AU AU2023222915A patent/AU2023222915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190127418A1 (en) | 2019-05-02 |
| AU2023222915A1 (en) | 2023-09-21 |
| CN109563125A (zh) | 2019-04-02 |
| IL285146A (en) | 2021-08-31 |
| CN115925780A (zh) | 2023-04-07 |
| KR20220120716A (ko) | 2022-08-30 |
| JP2022120138A (ja) | 2022-08-17 |
| JP7092744B2 (ja) | 2022-06-28 |
| WO2018018011A3 (en) | 2018-03-01 |
| AU2017298984A1 (en) | 2019-02-07 |
| MA45721A (fr) | 2019-05-29 |
| KR102435801B1 (ko) | 2022-08-25 |
| CN109563125B (zh) | 2022-08-09 |
| AU2017298984B2 (en) | 2023-08-31 |
| US11312745B2 (en) | 2022-04-26 |
| SG11201900573UA (en) | 2019-02-27 |
| CA3218290A1 (en) | 2018-01-25 |
| KR102579850B1 (ko) | 2023-09-18 |
| CA3031469A1 (en) | 2018-01-25 |
| KR20190037247A (ko) | 2019-04-05 |
| IL264375A (en) | 2019-02-28 |
| JP7411020B2 (ja) | 2024-01-10 |
| JP2019528255A (ja) | 2019-10-10 |
| IL264375B (en) | 2021-09-30 |
| MX2019000903A (es) | 2019-05-15 |
| EP3487867A2 (en) | 2019-05-29 |
| IL285146B (en) | 2022-09-01 |
| WO2018018011A2 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006291A (es) | Metodos para purificar proteinas que contienen fc. | |
| WO2013177115A3 (en) | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography | |
| WO2006012415A3 (en) | Rage protein derivatives | |
| CA2903496C (en) | Methods of increasing protein purity using protein a based chromatography | |
| JP2016530533A5 (es) | ||
| EA200970231A1 (ru) | СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ | |
| WO2006138553A3 (en) | Methods of purifying fc region containing proteins | |
| MX2015005178A (es) | Purificacion de polipeptidos usando ultrafiltracion de flujo tangencial de etapa doble. | |
| WO2010151632A8 (en) | Protein purification by caprylic acid (octanoic acid ) precipitation | |
| US20210139535A1 (en) | Method for purifying antibodies | |
| MX2020000288A (es) | Cromatografia. | |
| MX2011008759A (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| NZ781138A (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP2017121255A5 (es) | ||
| MX2021012251A (es) | Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). | |
| JP2017514803A (ja) | ゴナドトロピンの新規の精製方法 | |
| JP2016529489A5 (es) | ||
| MX2018005831A (es) | Gradientes de ph-sal opuestos para separaciones de proteina mejoradas. | |
| Matlschweiger et al. | Secretory immunoglobulin purification from whey by chromatographic techniques | |
| AU2020368409A1 (en) | Methods for characterizing host-cell proteins | |
| Reese et al. | Novel peptoid-based adsorbents for purifying IgM and IgG from polyclonal and recombinant sources | |
| MX2021013646A (es) | Dominios variantes para las proteínas multimerizantes y su separación. | |
| JP6399563B2 (ja) | Ｗｎｔ蛋白質の製造方法および保存方法 | |
| WO2005058362A3 (en) | Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules | |
| WO2017142388A3 (es) | Composición farmacéutica de proteínas híbridas recombinantes capaces de generar anticuerpos neutralzantes en contra del veneno de alacranes |